O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients
Open Access
- 15 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (1), 28-36
- https://doi.org/10.1093/neuonc/nop003
Abstract
O6-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of glioblastoma multiforme (GBM) patients. However, whether the MGMT status in GBM patients should be detected at the level of promoter methylation or protein expression is still a matter of debate. Here, we compared promoter methylation (by methylation-specific polymerase chain reaction) and protein expression (by Western blot) in tumor cell explants with respect to prediction of TMZ response and survival of GBM patients (n = 71). Methylated MGMT gene promoter sequences were detected in 47 of 71 (66%) cases, whereas 37 of 71 (52%) samples were scored positive for MGMT protein expression. Although overall promoter methylation correlated significantly with protein expression (χ2 test, P < .001), a small subgroup of samples did not follow this association. In the multivariate Cox regression model, a significant interaction between MGMT protein expression, but not promoter methylation, and TMZ therapy was observed (test for interaction, P = .015). In patients treated with TMZ (n = 42), MGMT protein expression predicted a significantly shorter overall survival (OS; hazard ratio [HR] for death 5.53, 95% confidence interval [CI] 1.76–17.37; P = .003), whereas in patients without TMZ therapy (n = 29), no differences in OS were observed (HR for death 1.00, 95% CI 0.45–2.20; P = .99). These data suggest that lack of MGMT protein expression is superior to promoter methylation as a predictive marker for TMZ response in GBM patients.Keywords
This publication has 48 references indexed in Scilit:
- Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with TemozolomideJapanese Journal of Clinical Oncology, 2007
- Molecular genetic markers as predictors of response to chemotherapy in gliomasCurrent Opinion in Oncology, 2007
- The Fallacy of Single-Agent Chemotherapy for CancerJournal of Clinical Oncology, 2007
- Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastomaBritish Journal of Cancer, 2007
- O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapiesMolecular Cancer, 2007
- Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in miceCarcinogenesis: Integrative Cancer Research, 2006
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Recent developments in the use of chemotherapy in brain tumoursEuropean Journal Of Cancer, 2006
- O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell LinesClinical Cancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005